91.19 0.00 (0.00%)
After hours: 6:15PM EST
|Bid||89.90 x 800|
|Ask||91.94 x 4000|
|Day's Range||90.54 - 92.28|
|52 Week Range||78.74 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.94|
|Expense Ratio (net)||0.13%|
A relentless bull says it's safe to buy tech again. With Wells Fargo's Scott Wren, CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Guy Adami.
We're going higher and a Jonathan Golub, Credit Suisse, tells you how to play the year-end rally. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Pete Najarian, Steve Grasso and Guy Adami.
Wells Fargo's Christopher Harvey says don't worry, the rally is on the way. Is value back in vogue? With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Steve Grasso and Guy Adami.
Julian Emanuel, BTIG, says investors shouldn't panic here, and discusses whether there's more market volatility ahead. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.
John Sculley, RX Advance chairman and former CEO of Apple, joins 'Squawk Alley' to discuss how the healthcare industry is going to change following the midterm elections.
The US jobs report for November was released today. The job additions came in at 155,000 as compared to consensus expectations of 198,000. While job additions in manufacturing remained strong at 27,000, construction net adds declined to 5,000.
In the last five years, AbbVie (NYSE:ABBV) stock is up 76%, which is impressive. Coming into today, AbbVie is down 5% in a year. The fundamentals, although very strong, are under attack from headlines about tariff wars especially between the United States and China.
The non-farm payrolls for October in the US (IVV) (QQQ) were 250,000 in October, which far outpaced economists’ consensus of 190,000. The strong job additions came after lackluster September additions of 134,000, which were further revised downward to 118,000 in October. After last month’s strong job additions, economists are expecting payrolls to come in at 200,000, which is below October’s payrolls but still healthy.
The outlook on GlaxoSmithKline PLC's credit rating was revised to negative from stable at Moody's Investors Service, which cited the drug giant's proposed acquisition of Tesaro Inc. . Moody's affirmed Glaxo's A2 long-term credit rating and its Prime-1 short-term rating. "We have changed [Glaxo's] outlook to negative as the company will deleverage more slowly than expected following the acquisition of Tesaro," said Moody's analyst Knut Slatten. "While the acquisition allows for a solid strengthening of [Glaxo's] oncology franchise, we expect credit metrics to remain weak for a prolonged period of time." Glaxo announced Monday an agreement to buy Tesaro in a cash deal valued at $5.1 billion, including debt. Glaxo's stock has gained 8.1% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has rallied 12.8% and the S&P 500 has edged up 1.0%.
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.
In a note published last week, Bank of America Merrill Lynch equity and quantitative strategist Savita Subramanian said, “We believe the peak in equities is likely before the end of 2019.” She expects equities to slow down next year as credit conditions tighten and earnings growth slows. As the Fed keeps tightening monetary conditions, equities (QQQ) (IVV), which are now accustomed to easy money, will find themselves in a difficult situation.
Thermo Fisher Scientific (TMO) stock rose from $189.88 at the close of market on December 29, 2017, to $235.01 at the close of market on November 23, 2018, representing a rise of ~24% year-to-date. On November 23, Thermo Fisher Scientific stock closed the day at $235.01, a ~29% rise from its 52-week low of $181.51 on December 5, 2017. On November 8, Thermo Fisher Scientific declared a fourth-quarter cash dividend of $0.17 per share. It announced that it would pay the dividend on January 15, 2019, to shareholders on record at the close of market on December 17, 2018.
Humana Inc. announced Wednesday a $750 million accelerated stock repurchase program, with final settlement expected to occur in the first quarter of 2019. Based on Tuesday's stock closing price of $309.63, the ACR represents about 2.42 million shares, or about 1.8% of the shares outstanding. Separately, the health care company raised its 2019 individual Medicare Advantage estimate to 350,000 to 400,000 members from 250,000 to 300,000 members, citing a higher than forecasted retention of existing members and sales. For prescription drug plans (PDP), it now expects a membership decline of 750,000 to 800,000 members for 2019, compared with its previous estimate of a decline of 500,000, given the competitive nature of the industry and pricing discipline. Humana also affirmed its 2018 adjusted earnings per share estimate of $14.40, which compares with the FactSet consensus of $14.43. The stock, which was still inactive in premarket trade, has lost 7.1% over the past three months, while the SPDR Health Care Select Sector ETF has slipped 0.9% and the S&P 500 has dropped 7.4%.
The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...
Plenty of sector exchange traded funds have been battered since the start of the fourth quarter, but some defensive plays are performing less poorly than growth and momentum fare. For example, the Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, is down just 1.6% in the current quarter. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
Shares of Johnson & Johnson fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent. In J&J's third-quarter ended Sept. 30, Zytiga sales rose 43.2% from a year ago to $958 million, making it the company's third-highest selling drug. Jennifer Taubert, worldwide chairman of pharmaceuticals at J&J, said in the company's post-earnings conference call with analysts while the company was "pleased" with Zytiga, "we're absolutely not dependent on it," according to a transcript provided by FactSet. The company said total pharmaceutical operational sales growth was 8.2%, but if Zytiga was removed, growth would have still been a "really strong" 6.6%. The stock has still gained 4.6% over the past three months, while the SPDR Health Care Select Sector ETF has slipped 1.7% and the Dow has lost 4.6%.
As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth year-to-date. Pfizer’s stock price closed at $43.51 on November 16, which represents ~31% growth from its 52-week low of $33.20 on February 9.
With the mid-term election dust settling, ETF investors can now consider the state of sector investing and look to opportunities that may lie ahead. On the recent webcast (available On Demand for CE Credit), ...
ETF investors who want to gain targeted exposure in the markets today should consider traditional and new economy sector-based strategies that could help align portfolios with market events, harness macro ...